MedTrace Logo

Visual Outcomes of Vivity in Patients With High Axial Length

NCT05210569 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2025-03-11

Study results available
· View outcomes & findings →

Summary

The objective is to assess the visual outcomes and quality of vision of patients receiving the AcrySof® Vivity Intraocular lens (IOL), when implanted in eyes with high ocular axial length (≥24.5mm), after uneventful cataract surgery.

Conditions

  • Cataract

Interventions

DEVICE

Vivity

Vivity intraocular lens (IOL)

Sponsors & Collaborators

  • Sengi

    collaborator INDUSTRY

  • Dr. James J. Wiens Medical Corporation

    lead OTHER

Principal Investigators

  • James J Wiens, MD · Dr. James J. Wiens Medical Corporation

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-13
Primary Completion
2023-09-06
Completion
2023-09-06
FDA Device
Yes

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05210569 on ClinicalTrials.gov